Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors
Otolaryngology–Head and Neck Surgery · 2026-05 · 174 (5) · 1289-1297
DOI: 10.1002/ohn.70191 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, published online on 2026-03-07. Written by Kaitlyn A Brooks and 11 co-authors. Institution: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Major MEDLINE topics: Hearing Loss, Immune Checkpoint Inhibitors, Ototoxicity. 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Objective
Hearing loss from immune checkpoint inhibitors (ICIs) has been documented in case reports and case series. We present the largest retrospective study investigating the rate of ICI‐related ototoxicity in a monitored cohort of platinum‐naïve patients. Study Design Retrospective cohort study.
Setting
Tertiary‐care center.
Methods
Patients treated with ICI between January 1, 2017, and December 31, 2022, with baseline and post‐treatment audiograms, were included. Patients with a history of platinum‐based chemotherapy were excluded. Demographics, oncologic diagnosis, ICI treatment details, and temporal bone irradiation (TBRT) were recorded. Audiometric thresholds were compared before and after ICI therapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Secondary outcome measures included changes in hearing using the American Speech‐Language‐Hearing Association (ASHA) and TUNE criteria.
Results
Among 15,390 ICI recipients, 29 platinum‐naïve patients met the inclusion criteria. Six of 29 patients (20.7%) experienced a CTCAE grade 1 or higher hearing loss. The proportions of hearing loss as defined by ASHA and TUNE criteria were 44.8% and 27.6%, respectively. The length of time between baseline and follow‐up audiograms was significantly longer among patients with hearing loss (mean difference [days]: CTCAE: 590.3, P < .01; ASHA: 280.9, P = .05; and TUNE: 122.1, P = .46). No other potential covariates believed to be confounders were significantly associated with the outcome.
Conclusion
A significant proportion of our monitored platinum‐naïve ICI patients met hearing‐loss criteria. Prospective studies with standardized audiologic surveillance are needed to further quantify the true incidence of ICI ototoxicity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID profiles: Kaitlyn A Brooks, Aung Naing, Jack Phan, Katherine Hutcheson, Xin Wang, Paul W Gidley, Marc-Elie Nader
Cite
APA
Brooks, K. A., Gidley, C. G., Grimley, O., Wang, C., Jivani, S., Roberts, D., Naing, A., Phan, J., Hutcheson, K., Wang, X., Gidley, P. W., & Nader, M. E. (2026). Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors. Otolaryngology–Head and Neck Surgery, 174(5), 1289-1297. https://doi.org/10.1002/ohn.70191
Vancouver
Brooks KA, Gidley CG, Grimley O, Wang C, Jivani S, Roberts D, et al. Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors. Otolaryngology–Head and Neck Surgery. 2026;174(5):1289-1297. doi:10.1002/ohn.70191
BibTeX
@article{Brooks2026,
author = {Brooks, Kaitlyn A and Gidley, Christopher G and Grimley, Olivia and Wang, Catherine and Jivani, Shirin and Roberts, Dianna and Naing, Aung and Phan, Jack and Hutcheson, Katherine and Wang, Xin and Gidley, Paul W and Nader, Marc-Elie},
title = {Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
volume = {174},
number = {5},
pages = {1289--1297},
doi = {10.1002/ohn.70191}
}
EUVIMED